Combination therapy with rituximab and cyclophosphamide in the treatment of anti-neutrophil cytoplasmic antibodies (ANCA) positive pulmonary hemorrhage: Case report

Pediatric Rheumatology

Volumn 9, Issue , 2011, Pages

  Baird, Emily M ^a   Lehman, Thomas J A ^b   Worgall, Stefan ^b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b Cornell University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HELIUM; HEMOGLOBIN; HYPERTENSIVE AGENT; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB; SURFACTANT;

ARTICLE; ARTIFICIAL VENTILATION; BLOOD TRANSFUSION; BRONCHOSCOPY; CASE REPORT; CHILD; COUGHING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; EPSTEIN BARR VIRUS; FEMALE; FEVER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCAPNIA; HYPOXEMIA; IMMUNOASSAY; LUNG EMPHYSEMA; LUNG HEMORRHAGE; NOSE CONGESTION; PLEURA EFFUSION; PRIORITY JOURNAL; PSEUDOMONAS; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; RETICULOCYTOSIS; RHINORRHEA; SCHOOL CHILD; STOMACH PAIN; STREPTOCOCCAL PHARYNGITIS; THORAX RADIOGRAPHY; VOMITING;

EID: 80054957530     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-9-33     Document Type: Article

References (16)

1. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener's granulomatosis: An analysis of 158 patients. Ann Intern Med 1992, 116:488-498.
2. Mukhtyar C, Guillevin L, Cid MC, EUL Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R, . European AR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009, 68:310-317. 10.1136/ard.2008.088096, 18413444, European.
3. de Groot K, Harper L, Jayne DRW, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, . EUVAS (European Vasculitis Study Group) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trail. Ann Intern Med 2009, 150:670-680. EUVAS (European Vasculitis Study Group).
4. Chen M, Kallenberg CG. ANCA-associated vasculitides--advances in pathogenesis and treatment. Nat Rev Rheumatol 2010, 6(11):653-64. Epub 2010 Oct 5, 10.1038/nrrheum.2010.158, 20924413.
5. Niles J. Rituximab in induction therapy for anti-neutrophil cytomplasmic antibody (ANCA) vasculitis. Clin Exp Immunol 2011, 164(Suppl 1):27-30.
6. Geetha D, Seo P, Specks U, Fervenza FC. Successful induction of remission with rituximab for relapse of ANCA-associated vasculitis post-kidney transplant: report of two cases. Am J Transplant 2007, 7(12):2821-5. Epub 2007 Oct 1, 10.1111/j.1600-6143.2007.01985.x, 17908274.
7. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza F, Geetha D, Keogh KA, Dissin EY, Monach PA, Peikert T, Stegemen C, Ytterberg SR, Specks U, . RAVE-ITN Research Group Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 36393:221-32. RAVE-ITN Research Group.
8. Keog KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006, 173(2):180-7. 2662987, 16224107.
9. Jones RB, Jan Willem Cohen T, Hauser T, Luqmani R, Morgan MD, Au Peh C, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DRW, . the European Vasculitis Study Group Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. The New England Journal of Medicine 2010, 363:211-220. 10.1056/NEJMoa0909169, 20647198, the European Vasculitis Study Group.
10. Narshi CB, Haider S, Ford CM, Isenberg DA, Giles IP. Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. Rheumatology 2010, 49(2):392-394. Epub 2009 Nov 19, 10.1093/rheumatology/kep356, 19926673.
11. Barillas L, Adams A, Angeles ST, MacDermott EJ, Barinstein L, Lehman TJA. Combination Cyclophosphamide and Rituximab for the Treatment of Childhood Onset SLE. Arthritis and Rheumatism 2006, 54(suppl):S689-90.
12. Lehman TJA. Lupus Nephritis Treated With Cyclophosphamide and Rituximab: A Case Study. Lupus Foundation of America, Inc
13. Adams A, Barillas-Arias L, Angeles ST, MacDermott EJ, Barinstein L, Lehman TJA. Cyclophosphamide and Rituximab Combination Therapy for the Treatment of Juvenile-Onset Scleroderma: 6 Patient Case Series. American College of Rheumatology 2006, 290. Poster Presentation.
14. Casian A, Jayne D. Management of alveolar hemorrhage in lung vasculitides. Semin Respir Crit Care Med 2011, 32(3):355-45.
15. Casian A, Jayne D. Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangitis, Churg-Strauss syndrome and renal limited vasculitis. Curr Opin Rheumatol 2011, 23(1):12-7. 10.1097/BOR.0b013e32834120c1, 21124082.
16. Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Hauser T, Neumann I, Tesar V, Wissing KM, Pagnoux C, Schmitt W, Jayne DR, . European Vasculitis Study Group (EUVAS) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010, 304(21):2381-8. Epub 2010 Nov 8, 10.1001/jama.2010.1658, 21060104, European Vasculitis Study Group (EUVAS).